April 5, 2012 – Siemens Healthcare has announced that the Somatom Definition Flash dual-source computed tomography (CT)
system with the new Stellar Detector – the first fully integrated detector that virtually eliminates electronic noise – has been cleared by the Food and Drug Administration (FDA) for sale and distribution in the United States. The new Stellar Detector further enhances the already outstanding Somatom Definition Flash CT system by delivering high spatial resolution, generating ultra-thin slices and providing an outstanding level of sharpness in CT at impressively low levels of patient radiation. With the combination of the Somatom Definition Flash CT system and the new Stellar Detector, even the finest image details can now be visualized. 

April 5, 2012 - SK Capital Partners, a U.S. based private investment firm, and IBA (Ion Beam Applications S.A.) announced
that they have closed on their previously announced agreement to create IBA Molecular, a jointly-owned company derived from IBA’s worldwide radiopharmaceutical division. IBA Molecular is a worldwide leader in the manufacturing and distribution of radioactive isotopes used for medical imaging and therapy, with over 50 locations in the United States, Europe and Asia and employs over 1,000 people. The transaction is valued at approximately €180 million ($239 million). SK Capital will own 60 percent of the recapitalized entity and IBA will retain a 40 percent stake.

April 5, 2012 — Arterial Remodeling Technologies (ART) reported yesterday that in vivo data strongly suggest that its next-generation bioresorbable stent promotes positive arterial remodeling in a post-angioplasty porcine model at six months follow-up. In addition, acute safety data indicate there have been more than 300 MACE-free consecutive implantations of its bioresorbable stent in its preclinical phase of development.

April 4, 2012 — Medtronic Inc. announced that the Symplicity renal denervation system provides safe, significant and sustained blood pressure reduction up to three years in patients with treatment-resistant hypertension, according to data from two clinical trials presented at the American College of Cardiology (ACC) 61st Annual Scientific Session.

April 4, 2012 — Edwards Lifesciences Corp. reported that longer-term results (? 2 years) from the high-risk Cohort A of the PARTNER Trial – a randomized comparison of patients treated with either surgical aortic valve replacement or the Edwards SAPIEN transcatheter heart valve – were published in The New England Journal of Medicine. The data were concurrently presented at the American College of Cardiology's (ACC) 61st Annual Scientific Session in Chicago.

April 4, 2012 — Medrad (Bayer) recently introduced the Mark 7 Arterion angiographic contrast injection system. The system is much smaller, lighter-weight, more ergonomic and easier to maneuver than previous Medrad injectors. It also is easier to operate than previous models, requiring less time to position and set up. It has a clearly visible and intuitive user interface to guide the user through proper set-up, and highlights the information need to perform injections.

New guidelines for CT-guided biopsies of lung nodules significantly reduce radiation exposure, allowing individuals the benefit of the procedure, which may cut down on overall lung cancer deaths. This research was presented at the Society of Interventional Radiology's (SIR) 37th Annual Scientific Meeting in San Francisco.

Incidences of renal complications, specifically acute renal failure (ARF) and new hemodialysis (HD), continue to increase significantly among Medicare beneficiaries (MB) admitted for percutaneous coronary intervention (PCI). This was according to a study presented last week at the American College of Cardiology’s (ACC) 61st Annual Scientific Session.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now